Efficacy of Anti-Interleukin-2 Receptor Antibody in Reducing the Incidence of Acute Rejection After Renal Transplantation
暂无分享,去创建一个
[1] A. Nobakht Haghighi,et al. Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation , 2012, Nephro-urology monthly.
[2] G. Ciancio,et al. Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation , 2009, Biologics : targets & therapy.
[3] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[4] D. Brennan,et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.
[5] J Neylan,et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. , 1998, The New England journal of medicine.